The apolipoprotein E4 allele frequency was significantly higher in patients with type V hyperlipoproteinemia compared to normal volunteers (51.7% vs 13.5%, p<0.01).
Case-Control (n=67)
No
The apolipoprotein E4 allele is significantly more prevalent in patients with type V hyperlipoproteinemia, suggesting it may play a role in the pathogenesis of the disorder.
Absolute Event Rate: 51.7% vs 13.5%
p-value: p=<0.01
A B S T R A C T Type V hyperlipoproteinemia (HLP) is characterized clinically by hepatosplenomegaly, occasional eruptive xanthomas, and an increased incidence of pancreatitis. These patients have striking hy- pertriglyceridemia due to increased plasma chylomi- cron and very low density lipoprotein concentrations in the fasting state, without a deficiency of lipoprotein lipase or its activator protein, apolipoprotein (apo) C-II. ApoE, a protein constituent of triglyceride-rich li- poproteins, has been implicated in the receptor-me- diated hepatic uptake of these particles. ApoE has three major alleles: E2, E3, and E4, and the products of these alleles are apoE2, apoE3, and apoE4, respec- tively. ApoE phenotypes were determined in 30 type V HLP patients as well as in 37 normal volunteers. Among the type V patients, 33.3% were noted to be homozygous, and 40.0% heterozygous for E4 (normal, 2.7 and 21.6%, respectively). These data suggest that apoE4 may play a role in the etiology of the hyperlipidemia in a significant number of type V HLP patients.
Ghiselli et al. (Sun,) conducted a case-control in Type V hyperlipoproteinemia (n=67). Type V hyperlipoproteinemia vs. Normal volunteers was evaluated on Apolipoprotein E4 allele frequency (p=<0.01). The apolipoprotein E4 allele frequency was significantly higher in patients with type V hyperlipoproteinemia compared to normal volunteers (51.7% vs 13.5%, p<0.01).